Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

39.48 +0.33 (+0.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
Where Cytokinetics Stands With Analysts
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings: 
Via Benzinga
Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients
Cytokinetics Incorporated (NASDAQ: CYTK) has announced  
Via Benzinga
Expert Ratings For Cytokinetics
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings with... 
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
Why Orphan Drug Designation Offers Several Benefits
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we... 
Via FinancialNewsMedia
Exposures Product Safety
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Monday
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading. 
Via Benzinga
Cytokinetics: Q1 Earnings Insights
Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated... 
Via Benzinga
70 Biggest Movers From Friday
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
Cytokinetics's Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients
Via Benzinga
Cytokinetics: Q4 Earnings Insights
Cytokinetics (NASDAQ:CYTK) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with Amazon Ads' demand-side platform. Absci... 
Via Benzinga
56 Biggest Movers From Friday
Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ: HGSH) shares... 
Via Benzinga
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021
Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE: 
Via Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK)... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Cytokinetics, Incorporated (CYTK) Q3 2021 Earnings Call Transcript
CYTK earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Where Cytokinetics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Cytokinetics (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.